Phenformin (cas 114-86-3)-loaded polymeric micelles for targeting both cancer cells and cancer stem cells in vitro and in vivo
-
Add time:08/25/2019 Source:sciencedirect.com
Conventional cancer chemotherapy often fails as most anti-cancer drugs are not effective against drug-resistant cancer stem cells. These surviving cancer stem cells lead to relapse and metastasis. In this study, an anti-diabetic drug, phenformin, capable of eliminating cancer stem cells was loaded into micelles via self-assembly using a mixture of a diblock copolymer of poly(ethylene glycol) (PEG) and urea-functionalized polycarbonate and a diblock copolymer of PEG and acid-functionalized polycarbonate through hydrogen bonding. The phenformin-loaded micelles, having an average diameter of 102 nm with narrow size distribution, were stable in serum-containing solution over 48 h and non-cytotoxic towards non-cancerous cells. More than 90% of phenformin was released from the micelles over 96 h. Lung cancer stem cells (side population cells, i.e. SP cells) and non-SP cells were sorted from H460 human lung cancer cell line, and treated with free phenformin and phenformin-loaded micelles. The results showed that the drug-loaded micelles were more effective in inhibiting the growth of both SP and non-SP cells. In vivo studies conducted in an H460 human lung cancer mouse model demonstrated that the drug-loaded micelles had greater anti-tumor efficacy, and reduced the population of SP cells in the tumor tissues more effectively than free phenformin. Liver function analysis was performed following drug treatments, and the results indicated that the drug-loaded micelles did not cause liver damage, a harmful side-effect of phenformin when used clinically. These phenformin-loaded micelles may be used to target both cancer cells and cancer stem cells in chemotherapy for the prevention of relapse and metastasis.
We also recommend Trading Suppliers and Manufacturers of Phenformin (cas 114-86-3). Pls Click Website Link as below: cas 114-86-3 suppliers
Prev:Original ArticleMelanocytes/MelanomaPhenformin (cas 114-86-3) Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma
Next:Graphene and CdS nanocomposite: A facile interface for construction of DNA-based electrochemical biosensor and its application to the determination of Phenformin (cas 114-86-3)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- ArticleLKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin (cas 114-86-3)08/29/2019
- Molecular and Cellular PharmacologyPhenformin (cas 114-86-3) has a direct inhibitory effect on the ATP-sensitive potassium channel08/28/2019
- Metformin and Phenformin (cas 114-86-3) block the peripheral antinociception induced by diclofenac and indomethacin on the formalin test08/27/2019
- Graphene and CdS nanocomposite: A facile interface for construction of DNA-based electrochemical biosensor and its application to the determination of Phenformin (cas 114-86-3)08/26/2019
- Original ArticleMelanocytes/MelanomaPhenformin (cas 114-86-3) Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma08/24/2019
- Original ArticleMelanocytes/MelanomaPhenformin (cas 114-86-3) Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma08/23/2019
- ReportPhenformin (cas 114-86-3), But Not Metformin, Delays Development of T Cell Acute Lymphoblastic Leukemia/Lymphoma via Cell-Autonomous AMPK Activation08/22/2019


